Abbott's MDx Sales Drop 2 Percent in Q2 | GenomeWeb

NEW YORK (GenomeWeb) – Abbott today reported that its diagnostics sales jumped 5 percent year over year in the second quarter, but molecular diagnostics was a drag on the business, falling 2 percent.

The medical products giant reported total revenues of $5.55 billion for the quarter ended June 30, up 2 percent from $5.45 billion for Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.